Download PDF

1. Company Snapshot

1.a. Company Description

BioLife Solutions, Inc.develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.


It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials.The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services.It markets and sells its products directly, as well as through third party distributors.


BioLife Solutions, Inc.was incorporated in 1987 and is headquartered in Bothell, Washington.

Show Full description

1.b. Last Insights on BLFS

The recent 3-month performance of BioLife Solutions, Inc. was negatively impacted by a quarterly loss of $0.01 per share, despite beating Zacks Consensus Estimate of a loss of $0.06. The company's GAAP net loss from continuing operations was $2.0 million in the fourth quarter, with a non-GAAP adjusted EBITDA of $4.0 million, or 18% of total revenue.

1.c. Company Highlights

2. BioLife Solutions Delivers Strong Q3 2025 Results with 31% Revenue Growth

BioLife Solutions reported a robust third quarter of 2025, with total revenue increasing by 31% year-over-year, driven by a 33% rise in cell processing revenue. The growth in revenue was accompanied by an expansion in adjusted EBITDA margin, which rose by 500 basis points to 28%. However, the company's EPS was $-0.33135, significantly below analyst estimates of $-0.02. The strong revenue growth and improved profitability were partly due to the sustained strength across the biopreservation media franchise and broader cell processing portfolio. With the sale of its evo Cold Chain logistics product line for approximately $25 million, the company is focusing on its core competencies and strengthening its balance sheet.

Publication Date: Nov -18

📋 Highlights
  • Revenue Growth:: Cell processing revenue surged 33% YoY, driving total revenue up 31% to $113.6M (Q3 2025).
  • Profitability Expansion:: Adjusted EBITDA margin widened 500 bps to 28%, reflecting higher-margin recurring revenue.
  • Asset Sale:: $25M cash sale of evo Cold Chain logistics product line strengthened balance sheet and refocused operations.
  • 2025 Guidance Raised:: Full-year revenue guidance lifted to $93M–$94M (26–28% YoY growth), total revenue now $95M–$96M (27–29% YoY growth).
  • 2026 Pricing Strategy:: 4–6% price increases planned, with actual growth outpacing list prices due to customer contract dynamics.

Guidance and Outlook

The company raised its full-year 2025 revenue guidance to $93 million to $94 million, representing a 26% to 28% year-over-year growth rate. BioLife expects strong momentum to continue into 2026, driven by commercial customers, and anticipates growth across all customer segments. The company will provide specific guidance for 2026 in January, once it receives forecasts from its large customers. Analysts currently estimate a revenue growth rate of 14.9% for next year.

Valuation and Financial Health

BioLife's current valuation metrics indicate a mixed picture. The stock trades at a P/S Ratio of 15.11 and an EV/EBITDA of -174.87, suggesting that the market is pricing in significant growth expectations. The company's P/E Ratio stands at -207.53, reflecting its current loss-making status. With an ROE of -1.61% and an ROIC of -4.85%, the company's return on equity and invested capital are negative. The Net Debt / EBITDA ratio is 1.23, indicating a manageable debt position. As Roderick de Greef stated, "we're confident in delivering sustainable revenue growth, margin expansion, and shareholder value creation in 2026 and beyond," which will be crucial in justifying the current valuation.

Operational Highlights and Future Plans

The company is focusing on cross-selling opportunities, having added one new headcount to its direct sales team, and is prioritizing its top 20 direct customers. BioLife is also making progress with its CryoCase customer evaluation, with the customer expressing interest in adopting the technology. The company is exploring adjacencies relative to its existing product line, with a focus on margin expansion and disciplined capital allocation. With commercial and late-stage clinical customers contributing over 50% of BPM revenue, BioLife is poised for continued growth.

3. NewsRoom

Card image cap

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys Shares of 9,524 BioLife Solutions, Inc. $BLFS

Nov -29

Source: defenseworld.net

Card image cap

BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence

Nov -20

Source: prnewswire.com

Card image cap

Campbell & CO Investment Adviser LLC Acquires Shares of 13,256 BioLife Solutions, Inc. $BLFS

Nov -18

Source: defenseworld.net

Card image cap

4 Medical Product Stocks to Watch From a Challenging Industry

Nov -17

Source: zacks.com

Card image cap

BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025

Nov -17

Source: prnewswire.com

Card image cap

BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript

Nov -07

Source: seekingalpha.com

Card image cap

BioLife Solutions, Inc. (BLFS) Surpasses Q3 Earnings and Revenue Estimates

Nov -06

Source: zacks.com

Card image cap

BioLife Solutions Reports Third Quarter 2025 Financial Results

Nov -06

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.81%)

6. Segments

Cell Processing - Product

Expected Growth: 14.0%

The 14.0% growth in Cell Processing - Product from BioLife Solutions, Inc. is driven by increasing demand for regenerative medicine, adoption of cell-based therapies, and expansion of biobanking services. Additionally, advancements in cell preservation and cryopreservation technologies, as well as growing investments in cell and gene therapy research, contribute to the segment's growth.

Freezer and Thaw - Product

Expected Growth: 15.0%

BioLife Solutions' Freezer and Thaw product growth is driven by increasing demand for regenerative medicine, cell and gene therapy, and biobanking applications. The 15.0% growth rate is also fueled by the product's ability to preserve and protect sensitive biological materials, as well as its compatibility with various cryogenic storage systems.

Biostorage Services - Service

Expected Growth: 17.0%

Biostorage Services' 17.0% growth is driven by increasing demand for biopreservation tools, expansion into new markets, and strategic partnerships. Growing adoption of regenerative medicine, cell and gene therapies, and personalized medicine also contribute to growth. Additionally, BioLife Solutions' investments in technology and infrastructure, as well as its strong sales and marketing efforts, support the segment's rapid expansion.

Biostorage Services - Rental

Expected Growth: 15.5%

Biostorage Services' 15.5% growth is driven by increasing demand for cryopreservation and cold chain logistics in cell and gene therapy, regenerative medicine, and biobanking. Expanding customer base, strategic partnerships, and investments in capacity expansion and technology advancements also contribute to growth.

Biostorage Services - Product

Expected Growth: 16.5%

Biostorage Services' 16.5% growth is driven by increasing demand for biopreservation tools, expansion into new markets, and strategic partnerships. Growing adoption of regenerative medicine, cell and gene therapies, and personalized medicine also contribute to growth. Additionally, BioLife Solutions' investments in technology and infrastructure, as well as its strong sales and marketing efforts, support the segment's rapid expansion.

Freezer and Thaw - Service

Expected Growth: 14.5%

BioLife Solutions' Freezer and Thaw service growth is driven by increasing demand for regenerative medicine, cell and gene therapy, and biobanking. The 14.5% growth rate is also fueled by the company's expanding customer base, strategic partnerships, and investments in product development and commercialization.

7. Detailed Products

CryoStor

A cryopreservation freeze media used to preserve living cells and tissues at very low temperatures.

HypoThermosol

A hypothermic storage solution used to preserve organs and tissues at low temperatures.

CryoStor CS10

A cryopreservation freeze media used to preserve stem cells and other cell types.

BioLife's Custom Biopreservation Media

Customized biopreservation media solutions for specific cell and tissue types.

evo Cold Chain 2-8°C Shipper

A cold chain shipping solution used to transport temperature-sensitive biologics.

8. BioLife Solutions, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

BioLife Solutions, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotechnology industry.

Bargaining Power Of Customers

BioLife Solutions, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are critical to its customers' operations, making it difficult for customers to negotiate prices.

Bargaining Power Of Suppliers

BioLife Solutions, Inc. relies on a few key suppliers for its raw materials, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate prices mitigate this risk.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements and regulatory hurdles. This makes it difficult for new entrants to enter the market and compete with established players like BioLife Solutions, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players competing for market share. BioLife Solutions, Inc. faces intense competition from companies with similar products and services, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 7.74%
Debt Cost 4.23%
Equity Weight 92.26%
Equity Cost 12.38%
WACC 11.75%
Leverage 8.39%

11. Quality Control: BioLife Solutions, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
AngioDynamics

A-Score: 4.6/10

Value: 7.8

Growth: 2.7

Quality: 4.5

Yield: 0.0

Momentum: 10.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
BioLife Solutions

A-Score: 3.9/10

Value: 4.4

Growth: 4.7

Quality: 4.7

Yield: 0.0

Momentum: 6.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Stereotaxis

A-Score: 3.8/10

Value: 6.2

Growth: 1.7

Quality: 3.7

Yield: 0.0

Momentum: 9.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Atrion

A-Score: 3.5/10

Value: 3.5

Growth: 3.0

Quality: 6.2

Yield: 1.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
STAAR Surgical

A-Score: 3.2/10

Value: 8.0

Growth: 4.1

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Ekso Bionics

A-Score: 3.0/10

Value: 8.6

Growth: 4.4

Quality: 3.9

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

25.46$

Current Price

25.46$

Potential

-0.00%

Expected Cash-Flows